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Summary In vitro (FLC-Vt) or in vivo (FLC-V) passaged Friend erythroleukaemia cells of DBA/2 origin
were tested for susceptibility to natural resistance (NR) in vivo or to NK cell activity in vitro. Scarcely
oncogenic FLC-Vt cells were highly susceptible to in vivo NR (measured as rapid organ clearance or growth
inhibition in lethally irradiated mice) or to in vitro NK attack. Conversely, highly oncogenic FLC-V cells were
weakly susceptible to NR and to NK as well. These data seem to point out that natural immunity, which is
up-regulated by endogenous or exogenous interferons, can play a significant role in surveillance against mouse
leukaemic cells of retrovirus origin.
It has been reported that the in vivo tumour suppressive
effects of interferon (IFN) against in vitro and in vivo
passaged Friend erythroleukaemia cells (FLC-Vt and FLC-
V, respectively), derived from DBA/2 mice infected with
Friend virus, might involve activation of immune host's
mechanism rather than acting directly on tumour cells
(Belardelli et al., 1982a; Gresser et al., 1983, 1988). This
hypothesis was based on the isolation of FLC clones
differing for sensitivity to IFN-alpha-beta-induced
antiproliferative effects under in vitro conditions (Affabris et
al., 1982). Using the highly tumorigenic IFN-sensitive (745)
or IFN-resistant (3C18) FLC-V clones it was demonstrated
that exogenous IFN preparations could suppress FLC-V in
vivo growth, irrespective of the differences in IFN sensitivity
(Belardelli et al., 1982a; Gresser et al., 1988). Moreover, it
was observed that the low oncogenicity of both 745- and
3C18-FLC-Vt clones was due to host's reactivity enhanced
by endogenous IFN, since pretreatment of mice with anti-
IFN antibodies augmented FLC-Vt tumorigenicity (Gresser
et al., 1983).
Previous investigations were carried out to detect the
possible origin of host's immune reactivity involved in the
indirect antitumour effects of IFN. The results showed that
in vivo natural resistance (NR) against both FLC-Vt (Iorio et
al., 1986) and FLC-V clones could play a significant role in
this system. The present study shows that the low oncogenic
FLC-Vt clone is subjected to strong NR in syngeneic DBA/2
mice and is more susceptible to NR effectors as compared
with the highly oncogenic FLC-V. Therefore the results of
this investigation further support the concept that the level
of oncogenicity of FLC is a function, at least in part, of




Inbred DBA/2 (H/2d) mice of different ages (Charles River,
Calco, Italy) were used.
Tumours
IFN-alpha-beta-sensitive 745 or -resistant 3Cl8 clones,
derived from DBA/2 committed erythroid stem cells infected
with Friend leukaemia virus and passaged either in vivo or in
vitro, were used (Affabris et al., 1982). FLC-V were
maintained in syngeneic DBA/2 mice by weekly serial
intraperitoneal (i.p.) transplantation of neoplastic cells. FLC-
Vt were routinely grown in RPMI-1640 medium
supplemented with 10% fetal calf serum. FLC-Vt are
considerably less tumorigenic when inoculated intraperi-
toneally (i.p.) or subcutaneously (s.c.) than FLC-V. The
features of the two cell clones used have been extensively
discussed elsewhere (Belardelli et al., 1984).
Drugs
Polyinosinic-polycytidylic acid (poly I:C) was obtained from
Sigma Chemical Company (St Louis, MO) and dissolved in
0.85% NaCl solution; carrageenan (iota-carrageenan) was
obtained from Sigma Chemical Company (St Louis, MO)
dissolved in 0.85% NaCl solution and heated in boiling
water for 10min; cyclophosphamide was supplied by Dr
V.L. Narayanan (Drug Synthesis and Chemistry Branch,
Division of Cancer Treatment, NCI, NIH, Bethesda, MD)
and dissolved in 0.85% NaCl solution.
Irradiation
Animals were subjected to total body irradiation using a
cobalt-60 irradiator (Hot Spot MKIV, Harwell, England),
delivering gamma-rays at the rate of 800Rmin-m.
Organ clearance of 125I-iodedeoxyuridine (125IUdR)-labelled
cells
The general procedure for this assay has been previously
described (Riccardi et al., 1980). Briefly 25 x 106 FLC-V or
FLC-Vt in 50ml of RPMI 1640 medium supplemented with
10% fetal calf serum were incubated overnight at 37°C in a
CO2 incubator in the presence of 5-10 ig of 5-fluoro-2'-
deoxyuridine (FUdR), to prevent endogenous thymidine
synthesis, and lOuCi of 125IUdR (5-iodo-2'-deoxyuridine)
(sp. act. 8.5mCimg-1; Amersham/Searle Corp., Arlington
Heights, IL). After washing with RPMI-1640 medium, cells
were adjusted to the desired concentration and injected
intravenously (i.v.) into DBA/2 mice (5-6 animals per group).
Four hours later the radioactivity of lungs was measured in
a well-type crystal scintillation counter (Packard Model
1510, Downers Grove, IL). The results are expressed as the
geometric mean of the percentage recovery of injected
radioactivity.
Evaluation of 125IUdR in vivo uptake by different organs
for testing cell proliferation
Lethally irradiated (800R) DBA/2 mice (6-8 animals per
group) challenged i.v. with FLC-V or FLC-Vt 2-4h after
irradiation were injected 4 days later with a single i.p. dose
(25pg per mouse) of FUdR to decrease the availability of
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endogenous thymidine. One hour later the mice were inocu-
lated with 0.5 pCi of 125IUdR in 0.25ml of 0.85% NaCl
solution. Spleens, livers and lungs were removed 3h later
and 125IUdR not incorporated into DNA was eluted by
soaking the organs in 70% ethanol for 3 days (Bennett,
1972). The incorporation of radioactivity was measured in a
gamma scintillation counter. The 125IUdR uptake was
expressed as the geometric mean of the percentage of the
isotope injected. (See also Hofer & Hughes, 1970.)
Cytotoxicity assay
The activity of natural killer (NK) cells was determined in a
51Cr release assay, as previously described (Herberman et al.,
1974). Briefly, graded numbers of effector spleen cells were
suspended in RPMI-1640 medium containing 10% heat
inactivated Newborn Calf Serum (Flow Laboratories, UK)
and 2% L-glutamine, admixed with 104 51Cr-labelled target
cells in U-shaped 96-well microtitre plates (Greiner, CA and
S6hne, Niirtingen, West Germany) in quadruplicate, in a
final volume of 0.2ml. The plates were incubated for 4h at
37°C in a 5% CO2 incubator. At the end of the incubation
the plates were centrifuged (800g for 10min) and the
radioactivity in 0.1 ml of the supernatant was measured in a
gamma-scintillation counter.
Calculation of the percentage of specific lysis
Experimental results were expressed as the percentage of
specific lysis over spontaneous release and were calculated as
follows:
Results
Survival of DBA/2 mice injected i.v. with graded numbers of
FLC-V or FLC-Vt
Previous studies demonstrated marked differences in tumori-
genicity of FLC-V and FLC-Vt after inoculation into synge-
neic DBA/2 mice mainly by i.p. or s.c. routes (Belardelli et
al., 1984). Tumour titration carried out in DBA/2 hosts
confirms that the same differences can be observed after i.v.
inoculation of both FLC-V or FLC-Vt (Table I). All mice
died after i.v. injection of 5 x 106 FLC-V and FLC-Vt, but
the median survival time (MTS) was significantly higher in
DBA/2 mice inoculated with FLC-Vt as compared with that
of mice injected with FLC-V. When 106 cells were used for
tumour challenge no animal death was detected in mice
inoculated with FLC-Vt, whereas all mice challenged with
FLC-V died with generalized leukaemia within 17 (745) or 13
(3C18) days. In addition, mortality ofmice recipient of FLC-
V was 100% following inoculum of 105 cells.
Weakening of in vivo resistance to FLC-Vt growth by
treatment with cyclophosphamide or sublethal irradiation
To assess the potential role of host's immunity in the low
tumorigenicity seen in normal syngeneic DBA/2 mice
injected i.v. with FLC-Vt, 106 in vitro passaged tumour cells
were injected i.v. into mice suppressed by 400 R or by
pretreatment with cyclophosphamide (200mgkg-1 i.p.). As
shown in Table II, the incidence of lethal growth in
immunosuppressed mice was 100%, whereas the majority of
non-treated mice survived beyond the 60-day observation
period.
% specific lysis -- X 100,
where c.p.m., is the mean c.p.m. released in the presence of
effector cells, c.p.m., is the mean c.p.m. released sponta-
neously by target cells, c.p.m.T is the total amount of 51Cr
incorporated into target cells.
Calculation of lytic units
Dose-response curves were obtained by plotting the percent-
ages of specific 51Cr release and the effector:target (E/T)
ratios. The best fit curve for this function was found to be
logarithmic in accordance with previous reports (Tentori et
al., 1985).
A lytic unit, LUn, was defined as the number of effector
cells, extrapolated from the dose-response curve, required to
achieve n% specific target cell lysis (Thorn & Herney, 1976).
The amount of LU,, per 106 cells was calculated by dividing
106 by the number of splenocytes corresponding to 1 LUn.
Statistical analysis
As for 125IUdR uptake test and clearance of radiolabelled
cells, the statistical analysis was performed according to
Student's t test calculated on the logs of the original c.p.m.
In the test for cell proliferation in lethally irradiated mice,
the 125IUdR background (i.e. that of irradiated mice not
subjected to lymphoma challenge) was substracted from the
125IUdR uptake of the test groups before calculations. For
survival studies, the non-parametric Mann-Whitney U test
was used.
Differences in cytolytic effects produced by NK effectors
in various experimental conditions were evaluated taking
into account the percent of specific cytotoxicity at all E/T
ratios. Therefore P values were calculated using covariance
analysis performed on the regression of the number of
effector cells over the logs of the percentage of specific 51Cr
release.
Table I Survival of DBA/2 mice inoculated i.v. with FLC-V
or FLC-Vt lines
In vivo In vitro
passaged passaged
(FLC-V) (FLC-Vt)
Tumour cells Dose MST' D/Tb MST D/T
FLC-745 5x 106 11 11/11 22* 11/11
FLC-745 106 12 6/6 >60** 0/6
FLC-745 105 15.5 6/6 n.d.c
FLC-3C18 5x 106 8 11/11 24* 7/7
FLC-3C18 106 10 5/5 >60** 0/6
FLC-3C18 105 13 5/5 n.d.
aMedian survival time (days); bdead over total mice tested;
Cn.d., not done.
*P<0.02; **P<0.01 according to Mann-Whitney U test,
comparing the mortality data of mice injected with FLC-V
with those of mice injected with FLC-Vt.
Table II Mortality of normal, cyclophosphamide-
pretreated or sublethally irradiated DBA/2 mice (8-
week old) after injection of 106 FLC-Vt
Tumour cells Pretreatment MST' DITb
FLC-745-Vt - >60 2/5
FLC-745-Vt cyclophosphamidec 17* 7/7
FLC-745-Vt 400Rd 17* 7/7
FLC-3C18-Vt - >60 1/7
FLC-3C18-Vt cyclophosphamide 22* 7/7
FLC-3C18-Vt 400 R 24* 7/7
aMedian survival time (days); bdead over total mice
tested; C200mgkg-1 i.p. -2 days; dmice were exposed
to 400 rads of gamma-rays 2h before tumour
injection.
*P<0.02 according to Mann-Whitney U test, com-
paring the mortality data of untreated mice with those
of cyclophosphamide-treated or irradiated mice.850 M. NERI et al.
Rapid in vivo elimination of 125IUdR-labelled FLC: age
dependence and comparison between FLC-V and FLC-Vt
Previous investigations pointed out that NR, measured as
rapid clearance of prelabelled cells, is detectable against both
FLC-Vt and FLC-V (Iorio et al., 1986, 1989). In the present
study a comparison between NR against FLC-V and FLC-Vt
in DBA/2 mice of different ages was performed. Mice were
injected i.v. with 104 FLC-V or FLC-Vt, labelled with
125IUdR, and lung clearance capability, considered to be the
most sensitive measure of NR (Riccardi et al., 1980), was
determined 4h later. The results, illustrated in Figure 1,
show that: (a) lung clearance of FLC-V or-Vt was not
statistically different in infant mice (18-20 days old); (b)
retained radioactivity in the lungs of adult mice (49 and 77
days old) was significantly lower in the animals inoculated
with FLC-Vt as compared with that of mice injected with
FLC-V; (c) the rate of clearance of leukaemia cells from
adult mice was significantly higher than that observed in
infant mice both for FLC-V and FLC-Vt.
Influence of the treatment with cyclophosphamide or
carrageenan on lung rapid clearance of FLC-V or FLC-Vt
DBA/2 mice untreated or pretreated with cyclophosphamide
or carrageenan were injected i.v. with 104 labelled FLC-V or
FLC-Vt. The results obtained, illustrated in Figure 2, show
that: (a) pretreatment with cyclophosphamide, carrageenan
or anti-Asialo GM-1 antiserum (see footnote of the figure)
significantly impaired lung clearance of FLC-V or FLC-Vt;
(b) significantly higher levels of radioactivity were found in
the lungs of untreated or cyclophosphamide pretreated
DBA/2 mice injected with FLC-V as compared with levels
found in the lungs of mice injected with FLC-Vt; (c) on the
contrary, clearance of FLC-V and FLC-Vt in mice depressed
for NR by carrageenan pretreatment did not show substan-
tial differences.
Comparison between the growth ofgraded numbers of FLC-
V or FLC-Vt in lethally irradiated mice
Previous studies (Kawano et al., 1986) demonstrated that the
distribution and survival of cells in the early phase after
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Figure 1 Lung rapid clearance of 104 125IUdR-labelled FLC-V
(open columns) or FLC-Vt (filled columns) (745 or 3C18 clones)
injected into syngeneic DBA/2 mice of different ages. The
statistical analysis was performed according to Student's t test,
comparing the logarithms of the recovery values. A, P<0.01
(FLC-V vs FLC-Vt); B, P<0.05 (FLC-V in infant (i.e. 18-20
days old) vs FLC-V in adult mice); C, P<0.01 (FLC-Vt in infant
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Figure 2 Lung rapid clearance of 2 x 104 125IUdR-labelled
FLC-V (open columns) or FLC-Vt (filled columns) (745 or 3C18
clones) injected i.v. into untreated or depressed for NR (cyclo-
phosphamide (Cy 300mgkg-1 i.p. day-1) or carrageenan (CAR,
1 mg mouse - day-1) pretreatment) syngeneic DBA/2 mice.
The statistical analysis was performed according to Student's I
test, comparing the logarithms of the recovery values. A, B or C,
P<0.01; A, FLC-V vs FLC-Vt; B, FLC-V in untreated mice vs
FLC-V in recipients pretreated with cyclophosphamide or carra-
geenan; C, FLC-Vt in untreated mice vs FLC-Vt in recipients
pretreated with cyclophosphamide or carrageenan. Treatment of
recipient mice with rabbit anti-Asialo GM-1 serum (Waco
Chemicals, West Germany, 25ul mouse-1 i.v., I day before test)
reduced leukaemia cell clearance in the lung by a factor of
approximately 2 in the case of FLC-V and of 20 in the case of
FLC-Vt. No substantial differences were found between 745 or
3C18 clones.
Table III Growth of graded numbers of FLC-V or FLC-Vt inocu-
lated i.v. into lethally irradiated (750 R) DBA/2 mice (7 weeks old)
% 125IUdR uptakea
Tumour cells Dose Spleen Liver
FLC-745-V 5 x 106 3.46(3.24-3.69) 1.35(i.22-1.49)
FLC-745-Vt 5 x 106 0.04(0.03-0.05)* 0.1 (0.09-0.14)*
FLC-745-V 2.5 x 106 1.41(i.31-1.53) 0.53(0.51-0.56)
FLC-745-Vt 2.5 x 106 0.05(0.04-0.06)* 0.13(0.12-0.14)*
FLC-745-V 106 0.85(0.79-0.92) 0.43(0.39-0.47)
FLC-745-Vt 106 0.03(0.02-0.04)* 0.08(0.07-0.10)*
FLC-3C18-V 5 x 106 4.42(3.28-5.95) 1.56(i.09-2.24)
FLC-3Ci8-Vt 5 x 106 0.05(0.04-0.06) 0.13(0.11i0.15)*
FLC-3C18-V 2.5 x 106 1.28(l.10-1.50) 1.07(0.93-1.24)
FLC-3Ci8-Vt 2.5 x 106 0.04(0.03-0.07)* 0.08(0.07-0.09)*
FLC-3C18-V 106 0.25(0.19-0.34) 0.85(0.73-0.98)
FLC-3Ci8-Vt 106 0.05(0.03-0.07)* 0.09(0.08-0.1i1)*
aPercentage of 125IUdR uptake (geometric mean) tested on day 4
after challenge. In parentheses the lower and upper limits of the
mean within its standard error. The percentage of 125IUdR uptake
in the lungs of mice injected with FLC-V or FLC-Vt was always less
than 0.05%.
*P<0.001 according to Student's t test, comparing the values of
percentage uptake found in mice injected with FLC-V with those
obtained in mice injected with FLC-Vt.
organ colonization potential. For this reason we decided to
investigate whether differences in sensitivity to NR measured
as rapid lung clearance between FLC-V and FLC-Vt could
be seen also in terms of growth in lethally irradiated mice
(Iorio et al., 1978). The results of the growth (4 days) of
FLC-V or FLC-Vt injected i.v. into lethally irradiated
DBA/2 mice are given in Table III. Using three differentMOUSE RESISTANCE TO FRIEND CELLS 851




Exp. Tumour cells Dose (weeks) Treatment Spleen Liver
I FLC-745-Vt 2 x 106 8 _ 0.04(0.02-0.06) 0.06(0.05-0.07)
FLC-745-Vt 2 x 106 8 cyclophosphamideb 0.05(0.03-0.07) 0.05(0.05-0.06)
FLC-745-Vt 2 x 106 8 carrageenanc 0.28(0.21-0.37)** 0.18(0.15-0.23)**
2 FLC-745-Vt 2 x 106 13 - 0.15(0.10-0.21) 0.08(0.07-0.09)
FLC-745-Vt 2 x 106 13 cyclophosphamide 0.42(0.34-0.52)* 0.09(0.08-0.10)
FLC-745-Vt 2 x 106 13 carrageenan 0.50(0.35-0.72)* 0.13(0.11-0.16)
3 FLC-3C18-Vt 2 x 106 8 _ 0.08(0.06-0.09) 0.07(0.06-0.08)
FLC-3C18-Vt 2 x 106 8 cyclophosphamide 0.04(0.03-0.05) 0.04(0.04-0.04)
4 FLC-3C18-Vt 2 x 106 10 - 0.04(0.03-0.04) 0.10(0.09-0.11)
FLC-3C18-Vt 2 x 106 10 cyclophosphamide 0.26(0.20-0.34)** 0.13(0.12-0.14)
5 FLC-3C18-Vt 5 x 10" 8 _ 0.03(0.02-0.04) 0.06(0.05-0.07)
FLC-3C18-Vt 5 x 106 8 carrageenan 0.14(0.08-0.23)* 0.18(0.16-0.21)**
aPercentage of'25IUdR uptake (geometric mean) tested on day 4 after tumour challenge. In parentheses
the lower and upper limits of the mean within its standard error; b300mgkg-1 i.p., day-1; C' mgmouse-
i.v., +3h.
*P<0.05, **P<0.01 according to Student's t test, comparing the values of percentage uptake found in
untreated mice with those obtained in mice treated with cyclophosphamide or carrageenan.
numbers of cells, a significantly higher proliferation was
always observed in the spleen and liver of mice inoculated
with FLC-V as compared with that found in mice injected
with FLC-Vt. Essentially no tumour proliferation was
observed in the lungs of mice inoculated with FLC-V or
FLC-Vt (see footnote Table III) and in the liver and spleen
of mice injected with FLC-Vt.
Effect of treatment with cyclophosphamide or carrageenan
on the growth of FLC-Vt injected i.v. into lethally irradiated
DBA/2 mice
In order to assess the role of natural immunity in impairing
tumour proliferation in lethally irradiated mice injected with
FLC-Vt, DBA/2 mice were immunosuppressed by treatment
with cyclophosphamide or carrageenan, lethally irradiated
and injected i.v. with FLC-Vt. The results of the growth of
FLC-Vt, monitored by 125IUdR uptake 4 days later, are
given in Table IV. Leukaemia cell proliferation was essen-
tially absent in control and in cyclophosphamide-pretreated
young (8 week old) DBA/2 mice injected i.v. with 2 x 106
FLC-745-Vt (exp. 1) or FLC-3C18-Vt (exp. 3). Significantly
higher leukaemia cell proliferation was observed in the
spleen of older DBA/2 mice (10-13 week old) pretreated
with cyclophosphamide as compared with that in recipient
controls (exp. 2 and 4). Treatment with carrageenan was
more efficient and induced a significantly higher proliferation
of FLC-Vt (both 745 and 3C18 clone) in the spleen and liver
of young (exp. 1 and 5) or old (exp. 2) DBA/2 hosts as
compared with that in untreated controls.
In vitro NK activity against FLC-V or FLC-Vt
Splenic NK activity of normal or Poly I:C stimulated
DBA/2 mice was tested against FLC-V or FLC-Vt. In
accordance with previous observations (Belardelli et al.,
1982a) FLC-V and FLC-Vt were resistant to NK-mediated
lysis of spleen cells obtained from untreated DBA/2 mice
(see footnote in Table V). On the other hand, a higher, but
limited susceptibility of FLC-Vt as compared with that of
FLC-V was observed when effector cells were collected from
Poly I:C stimulated donors (Table V).
Discussion
The results of the present paper show that the scarcely
oncogenic FLC-Vt clone is more susceptible to NR in vivo
and in vitro as compared with the highly oncogenic FLC-V.
This appears to be in line with the hypothesis that IFN
Table V Susceptibility of FLC clones to NK-
mediated cytotoxicity of spleen cells collected from
Poly I:C stimulated (5mgkg-1, day-1) DBA/2 mice
LU5/106b
Group Target
no. cellsa Mean (s.d.) pC
1 FLC-745-V 0.2(0.03-1.5) -
2 FLC-745-Vt 16.6(14.5-19.0) <0.01
3 FLC-3C18-V 5.7(3.9-8.3) -
4 FLC-3C18-Vt 11.3(8.8-14.6) <0.01
aEffector:target ratios used: 100: 1, 50:1, 25: 1; bLytic
units 5% per 106 effector cells. Data are expressed as
mean (mean-standard deviation; mean+standard
deviation). The splenic NK cytotoxic activity value of
untreated DBA/2 mice to FLC-V and FLC-Vt never
exceeded 3% of the mean; cP, probability, calculated
as illustrated in Materials and methods, comparing
groups 1 vs 2 and 3 vs 4.
could activate host-mediated mechanisms rather than directly
acting on tumour cells (Gresser et al., 1983).
A series of investigations has been undertaken in order to
elucidate the mechanism of the indirect effect of IFN on the
in vivo growth of tumour cells. Using models different from
FLC, Kataoka et al. (1984) demonstrated the involvement of
T-cell immunity, Uno et al. (1985) evidenced a positive
contribution of macrophages, and Hanna (1980) and Hanna
& Fidler (1980, 1981) observed that IFNs and IFN inducers
could limit metastases in mice by stimulation of NK-cell
system. However, other reports did not support the idea that
host's immune mechanisms are involved in the indirect effect
of IFN. Studies relative to the tumour model adopted in the
present paper showed that IFN-induced FLC-V necrosis was
not accompanied by host immunocyte infiltration (Belardelli
et al., 1982b). Therefore, it was proposed that IFN-
dependent elimination of tumour cells could be mediated by
various biochemical mechanisms such as changes in the
physicochemical conditions within the peritoneal cavity.
Moreover, Proietti et al. (1986), using 3 P-nuclear resonance
spectroscopy examinations, hypothesised that IFN could
exert some effects on FLC metabolism via altered host
microenvironment with subsequent tumour cell degeneration.
Investigations performed in our laboratory (Iorio et al.,
1986, 1989) examined the possibility that NR could be imnpli-
cated in the indirect role played by IFN on FLC growth in
mice. Host's immunity related to NR, measured in vivo as
rapid clearance of prelabelled cells, was found to be present
against FLC-V and FLC-Vt, independently from IFN-852 M. NERI et al.
sensitivity (Iorio et al., 1986, 1989). The results shown in the
present study were obtained by simultaneously measuring
and comparing within the same experiment the following
parameters concerning FLC-V and FLC-Vt: (a) mortality of
syngeneic DBA/2 hosts following i.v. injection of the
tumours; (b) specific organ retention of prelabelled cells at
4h after i.v. inoculation; (c) growth of FLC in lethally
irradiated mice; (d) susceptibility of the neoplastic cells to
the effectors of in vitro measured NK activity.
The results of survival experiments (Table I) showed that
FLC-V is more oncogenic than FLC-Vt when inoculated by
the i.v. route, thus confirming the previous observations
obtained injecting the same clones subcutaneously or intra-
peritoneally (Belardelli et al., 1984). In addition the role of
host's immunity was pointed out by the finding that resis-
tance to FLC-Vt could be weakened by total-body irradia-
tion or by pretreatment with an immunodepressive agent
such as cyclophosphamide used at high dose (i.e.
200mgkg-1 i.p., Table II).
The studies performed to measure the possible involve-
ment of NR in vivo in the low oncogenicity of FLC-Vt show
significantly higher rates in FLC-Vt or FLC-V clearance in
adult young mice as compared with that observed in infant
recipients, immature for NR (Figure 1). Moreover, signifi-
cantly higher amounts of radiolabelled cells were found in
FLC-V injected young adult mice as compared with those
detected in the hosts of the same age inoculated with FLC-
Vt. No differences were present, instead, in infant non-
immunocompetent mice. Depression of NR by pharmaco-
logical manipulation of the host (i.e. treatment with cyclo-
phosphamide, carrageenan or anti-Asialo-GM-1 serum)
induced a decline in the ability of mice to clear FLC-V
or FLC-Vt (Figure 2). It is conceivable that NR-depressive
agents act directly on NR-effector cells, including lung
macrophages and NR-accessory cells involved in the upregu-
lation of the natural immune function, possibly including
IFN-gamma-producing T-cells (Friedman & Vogel, 1983).
The results of studies carried out measuring in vivo growth
of FLC-V or FLC-Vt in lethally irradiated hosts are in
accordance with data obtained measuring the rapid clearance
of tumour cells. The proliferation of graded numbers of
FLC-V was significantly higher than that observed for FLC-
Vt (Table III). Actually no growth of FLC-Vt was observed
in untreated lethally irradiated DBA/2 hosts, whereas signifi-
cant proliferation occurred in mice pretreated with immuno-
depressive agents (Table IV).
Finally, the NK experiments in vitro confirmed that FLC-
Vt is more susceptible than FLC-V to NK-mediated lysis.
The observation that rapid in vivo clearance of FLC-Vt is
markedly more efficient than in vitro killing by NK effector
spleen cells, can be explained by at least two different
hypotheses: (a) lung effector cells are more cytotoxic than
splenocytes against FLC-Vt targets; (b) the kinetics of in vivo
clearance of leukaemic cells results from a mechanism more
complex than that underlying in vitro natural cell-mediated
cytotoxicity. The data of increased susceptibility to NK-
mediated lysis of FLC-Vt vs FLC-V are consistent with a
number of studies reporting that tumour cells become less
tumorigenic (Liu et al., 1977; Morgan et al., 1979; Beer et
al., 1983; Yamashina et al., 1986) and more easily lysed in
vitro by NK cells (Sendo et al., 1975; Nunn et al., 1977),
following in vitro cultivation. This often seems to be due to
increased immunogenicity presumably as a consequence of
changes on the membrane surface (Liu et al., 1977; Morgan
et al., 1979; Yamashina et al., 1986). In fact, Amici et al.
(1984), studying cell surface glycoproteins of FLC-V and
FLC-Vt, observed a modified type and/or rate of glycosyla-
tion of membrane proteins possibly responsible of the differ-
ences in oncogenicity.
In conclusion, the results of the present investigation point
to an important role of NR in the defence against Friend
virus erythroleukaemia cells, although the mechanism under-
lying the role played by IFN has not been directly and
definitely elucidated. In any case our data provide further
support to the studies on host's surveillance in Friend virus-
induced leukaemogenesis. Kumar et al. (1974) and Bennett et
al. (1976) suggested that the natural effector cells active in
haemopoietic graft rejection by lethally irradiated mice are
similar to those involved in 'genetic resistance' to Friend
virus leukaemia cells. Indeed, adult mice depleted of func-
tional NK cell activity and of reactivity against haemopoietic
histocompatibility (Hh) type antigens with the bone-seeking
isotope 89Sr are deficient in their ability to suppress Friend
virus erythroleukaemogenesis. Moreover, Eckner et al. (1987)
found that treatment with anti-Asialo-GM1 serum, capable
of depressing NK and Hh-type reactivity, elicited the rapid
development of dormant leukaemia induced with replication-
defective Friend polycythaemia-inducing spleens focus-
forming virus (SFFV,). Enhanced expression of Hh type
antigens, target for marrow graft rejection, was observed by
Rossi et al. (1970) and Cudkowicz et al. (1972) in DBA/2
spleen cells after in vivo infection with Friend leukaemia
virus. Finally NR, measured as growth in lethally irradiated
mice, was observed by Afifi et al. (1986) against FLD-3
erythroleukaemia, induced by Friend virus in BALB/c mice.
The work described in this paper was supported in part by grants
from Consiglio Nazionale delle Ricerche, Rome, Italy, Progetto
Finalizzato 'Oncologia', nos. 84.07577.44 and 87.02812.44.
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